Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.74 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.74 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.67 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.67 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.65 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837460 | 1.00 | HDAC1 (0.74) | HDAC1HDAC2HDAC8HDAC3HDAC4 | |
| SCHEMBL4838789 | 0.91 | SIRT5 (0.76) | HDAC1HDAC2HDAC8HDAC3HDAC4 | |
| SCHEMBL8269145 | 0.90 | HDAC1 (0.62) | HDAC1HDAC2HDAC8HDAC3HDAC4 | |
| SCHEMBL3504493 | 0.90 | HDAC1 (0.62) | HDAC1HDAC2HDAC8HDAC3HDAC4 | |
| SCHEMBL14254942 | 0.90 | HDAC1 (0.64) | HDAC1HDAC2HDAC8HDAC3HDAC4 | |
| SCHEMBL8312589 | 0.87 | HDAC1 (0.62) | HDAC1HDAC2HDAC8HDAC3HDAC4 | |
| SCHEMBL13928112 | 0.87 | HDAC1 (0.62) | HDAC1HDAC2HDAC8HDAC3HDAC4 | |
| SCHEMBL22034415 | 0.86 | SIRT5 (0.69) | HDAC1HDAC2HDAC8HDAC3HDAC4 | |
| SCHEMBL22034417 | 0.86 | SIRT5 (0.69) | HDAC1HDAC2HDAC8HDAC3HDAC4 | |
| SCHEMBL17742350 | 0.85 | SIRT2 (0.69) | HDAC1HDAC2HDAC8HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1231919-B1 | Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors | SLOAN KETTERING INST CANCER (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-1443928-B1 | TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN | SLOAN KETTERING INST CANCER (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2269609-A2 | Treatment of neurodegenerative diseases and cancer of the brain with SAHA | Sloan-Kettering Institute for Cancer Research (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2006-10-26 | — | — | US | disclosed |
| US-7126001-B2 | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-01 | — | — | US | disclosed |
| WO-2003032921-A2 | TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-04-24 | — | — | WO | disclosed |
| US-6511990-B1 | Selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC1 3/4885HDAC2 13/4885HDAC8 17/4885 |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC1 3/4885HDAC2 13/4885HDAC8 17/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC1 3/4885HDAC2 13/4885HDAC8 17/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | HDAC1 1102/4885HDAC2 2255/4885HDAC8 954/4885 |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC1 3/4885HDAC2 10/4885HDAC8 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.